

# Emerging Challenges In Primary Care: 2016

### **Activity Evaluation Summary**

**CME Activity:** Emerging Challenges in Primary Care: 2016

Saturday, September 17, 2016

Fort Lauderdale Marriott Coral Springs

Fort Lauderdale, FL

Course Director: Gregg Sherman, MD

**Date of Evaluation Summary:** October 3, 2016



In September 2016, the National Association for Continuing Education (NACE) sponsored a CME program, *Emerging Challenges in Primary Care: 2016*, in Fort Lauderdale, FL.

This educational activity was designed to provide primary care physicians, nurse practitioners, physician assistants and other primary care providers the opportunity to learn about varied conditions such as diabetes, ADHD in adults, pulmonary arterial hypertension, hypercholesterolemia, overactive bladder, and heart failure.

In planning this CME activity, the NACE performed a needs assessment. A literature search was conducted, national guidelines were reviewed, survey data was analyzed, and experts in each therapeutic area were consulted to determine gaps in practitioner knowledge, competence or performance.

Five hundred fifty five healthcare practitioners registered to attend *Emerging Challenges in Primary Care: 2016* in Fort Lauderdale, FL. Three hundred healthcare practitioners actually attended this conference. Each attendee was asked to complete and return an activity evaluation form prior to the end of the conference. Two hundred and ninety six completed forms were received. The data collected is displayed in this report.

### CME ACCREDITATION

The Association of Black Cardiologists, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The Association of Black Cardiologists, Inc. designates this live activity for a maximum of 3.25 *AMA PRA Category 1 Credits*<sup>TM</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The National Association for Continuing Education designates this live activity for a maximum of 4.0 *AMA PRA Category 1 Credits*<sup>TM</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

National Association for Continuing Education is approved as a provider of nurse practitioner continuing education by the American Association of Nurse Practitioners. AANP Provider Number 121222. This program has been approved for 7.25 contact hours of continuing education (which includes 3.25 pharmacology hours).

Maintenance of Certification: Successful completion of this activity, which includes participation in the evaluation component, enables the participant to earn up to 7.25 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity providers' responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Through the American Board of Medical Specialties ("ABMS") and Association of American Medical Colleges' ("AAMC") joint initiative (ABMS MOC Directory) to create a wide array of Maintenance of Certification ("MOC") Activities, Emerging Challenges in Primary Care has met the MOC requirements as a MOC Part II CME Activity by the following ABMS Member Boards: American Board of Family Medicine and American Board of Preventive Medicine.

### **Integrated Item Analysis Report**

### What is your professional degree?

| Response    | Frequency | Percent | Mean: - |
|-------------|-----------|---------|---------|
| MD          | 102       | 34.69   |         |
| DO          | 8         | 2.72    |         |
| NP          | 137       | 46.60   |         |
| PA          | 15        | 5.10    |         |
| RN          | 18        | 6.12    |         |
| Other       | 5         | 1.70    |         |
|             |           |         |         |
| No Response | 11        | 3.74    |         |

Indicate the number of patients you see each week in a clinical setting regarding each therapeutic area listed: ADHD:

| Response    | Frequency | Percent | Mean: 2.15 |
|-------------|-----------|---------|------------|
| None        | 73        | 24.83   |            |
| 1-5         | 154       | 52.38   |            |
| 6-10        | 34        | 11.56   |            |
| 11-15       | 13        | 4.42    |            |
| 16-20       | 7         | 2.38    |            |
| 21-25       | 6         | 2.04    |            |
| > 25        | 2         | 0.68    |            |
| No Response | 5         | 1.70    |            |

Indicate the number of patients you see each week in a clinical setting regarding each therapeutic area listed: Hypercholesterolemia:

| Response    | Frequency | Percent | Mean: 4.82 |
|-------------|-----------|---------|------------|
| None        | 21        | 7.14    |            |
| 1-5         | 20        | 6.80    |            |
| 6-10        | 32        | 10.88   |            |
| 11-15       | 41        | 13.95   |            |
| 16-20       | 44        | 14.97   |            |
| 21-25       | 49        | 16.67   |            |
| > 25        | 75        | 25.51   |            |
| No Response | 12        | 4.08    |            |

Indicate the number of patients you see each week in a clinical setting regarding each therapeutic area listed: Diabetes:

| Response    | Frequency | Percent | Mean: 4.37 |
|-------------|-----------|---------|------------|
| None        | 22        | 7.48    |            |
| 1-5         | 28        | 9.52    |            |
| 6-10        | 61        | 20.75   |            |
| 11-15       | 32        | 10.88   |            |
| 16-20       | 56        | 19.05   |            |
| 21-25       | 25        | 8.50    |            |
| > 25        | 61        | 20.75   |            |
| No Response | 9         | 3.06    |            |

Indicate the number of patients you see each week in a clinical setting regarding each therapeutic area listed: PAH:

| Response    | Frequency | Percent | Mean: 2.30 |
|-------------|-----------|---------|------------|
| None        | 86        | 29.25   |            |
| 1-5         | 112       | 38.10   |            |
| 6-10        | 37        | 12.59   |            |
| 11-15       | 21        | 7.14    |            |
| 16-20       | 9         | 3.06    |            |
| 21-25       | 7         | 2.38    |            |
| > 25        | 7         | 2.38    |            |
| No Response | 15        | 5.10    |            |

Indicate the number of patients you see each week in a clinical setting regarding each therapeutic area listed: OAB:

| Response    | Frequency | Percent | Mean: 3.03 |
|-------------|-----------|---------|------------|
| None        | 43        | 14.63   |            |
| 1-5         | 87        | 29.59   |            |
| 6-10        | 56        | 19.05   |            |
| 11-15       | 29        | 9.86    |            |
| 16-20       | 22        | 7.48    |            |
| 21-25       | 17        | 5.78    |            |
| > 25        | 14        | 4.76    |            |
| No Response | 26        | 8.84    |            |

Indicate the number of patients you see each week in a clinical setting regarding each therapeutic area listed: Heart Failure:

| Response    | Frequency | Percent | Mean: 3.33 |
|-------------|-----------|---------|------------|
| None        | 39        | 13.27   |            |
| 1-5         | 69        | 23.47   |            |
| 6-10        | 53        | 18.03   |            |
| 11-15       | 40        | 13.61   |            |
| 16-20       | 21        | 7.14    |            |
| 21-25       | 22        | 7.48    |            |
| > 25        | 22        | 7.48    |            |
| No Response | 28        | 9.52    |            |

Upon completion of this activity, I can now: Describe the role of the kidney in glycemic control; Review emerging data surrounding the effects of SGLT2 inhibitor therapy; Recognize the incidence and risk of hypoglycemia in managing patients with diabetes; Discuss approaches to individualizing the treatment of T2DM:

Response

Frequency Percent

Mean: 1.13

| Response    | Frequency | Percent | Mean: 1.13 |
|-------------|-----------|---------|------------|
| Yes         | 249       | 84.69   |            |
| Somewhat    | 37        | 12.59   |            |
| Not at all  | 0         | 0.00    |            |
|             |           |         |            |
|             |           |         |            |
|             |           |         |            |
|             |           |         |            |
| No Response | 8         | 2.72    |            |

Upon completion of this activity, I can now: Describe ADHD symptom profiles and common presentations in a primary care setting; Identify risks for coexisting disorders in adult patients with ADHD with emphasis on anxiety disorders, mood disorders, and substance use/abuse disorders; Implement appropriate pharmacologic treatment for adults diagnosed with ADHD designed to improve compliance, minimize side effects and maximize outcomes in a busy primary care setting; Use adult ADHD assessment and treatment tools for assessment, treatment and follow-up monitoring

| Response    | Frequency | Percent | Mean: 1.17 |
|-------------|-----------|---------|------------|
| Yes         | 243       | 82.65   |            |
| Somewhat    | 48        | 16.33   |            |
| Not at all  | 1         | 0.34    |            |
| No Response | 2         | 0.68    |            |

Upon completion of this activity, I can now: Explain the pathophysiology of pulmonary arterial hypertension (PAH); Determine when PAH should be suspected and how to determine the specific etiology including the importance of right heart catheterization and ventilation-perfusion (V/Q) scan; Define parameters that determine the severity of PAH; Review of treatments and how to appropriately refer and follow patients receiving treatment for PAH:

| Response    | Frequency | Percent | Mean: 1.21 |
|-------------|-----------|---------|------------|
| Yes         | 231       | 78.57   |            |
| Somewhat    | 60        | 20.41   |            |
| Not at all  | 1         | 0.34    |            |
| No Response | 2         | 0.68    |            |

Upon completion of this activity, I can now: Discuss the benefits of LDL-C lowering with pharmacologic therapies that improve cardiovascular outcomes; Define the appropriate use of non-statin medications in addition to statin therapy; Discuss the role of anti-PCSK9 monoclonal antibody therapy in LDL-C reduction to achieve cardiovascular risk reduction; Recognize and develop appropriate treatment strategies for special populations (women, elderly, ethnic minorities) that would benefit from lipid lowering therapy:

| Response    | Frequency | Percent | Mean: 1.09 |
|-------------|-----------|---------|------------|
| Yes         | 265       | 90.14   |            |
| Somewhat    | 22        | 7.48    |            |
| Not at all  | 2         | 0.68    |            |
| No Response | 5         | 1.70    |            |

Upon completion of this activity, I can now: Identify the patient with overactive bladder (OAB) in the office of the primary care physician (PCP) with a simple history, physical and appropriate labs; Identify interventions that can optimize OAB treatment and improve patient satisfaction; Discuss the management of refractory OAB utilizing pharmacologic and non-pharmacological treatments; Optimize adherence by enhancing communication in order to engage and partner with patients in the treatment plan:

| Response    | Frequency | Percent | Mean: 1.13 |
|-------------|-----------|---------|------------|
| Yes         | 233       | 79.25   |            |
| Somewhat    | 29        | 9.86    |            |
| Not at all  | 2         | 0.68    |            |
| No Response | 30        | 10.20   |            |

Upon completion of this activity, I can now: Know the risk factors for heart failure and the role of biomarkers in diagnosis and treatment; Recognize the importance of heart rate in cardiovascular risk of heart failure; Utilize the most recent clinical evidence to inform their decisions for the management of heart failure; Identify approaches to facilitate early recognition and optimization of heart failure management?; Describe pathophysiologic factors contributing to increased risk of heart failure among African Americans and other ethnic minorities:

Overall, this was an excellent CME activity:

| ResponseFrequencyPercentMeanYes20870.75Somewhat3712.59Not at all10.34 No Response 48 16.33 |             |           |         |            |  |  |
|--|-------------|-----------|---------|------------|--|--|
| Somewhat 37 12.59  Not at all 1 0.34   | Response    | Frequency | Percent | Mean: 1.16 |  |  |
| Not at all 1 0.34  | Yes         | 208       | 70.75   |            |  |  |
|  | Somewhat    | 37        | 12.59   |            |  |  |
| No Response 48 16.33   | Not at all  | 1         | 0.34    |            |  |  |
| No Response 48 16.33   |             |           |         |            |  |  |
| No Response 48 16.33   |             |           |         |            |  |  |
| No Response 48 16.33   |             | 40        | 40.00   |            |  |  |
| ·  | No Response | 48        | 16.33   |            |  |  |

| Response       | Frequency | Percent | Mean: 1.12 |
|----------------|-----------|---------|------------|
| Strongly Agree | 258       | 87.76   |            |
| Agree          | 31        | 10.54   |            |
| Neutral        | 2         | 0.68    |            |
| Disagree       | 0         | 0.00    |            |
| Strongly       | 0         | 0.00    |            |
| Disagree       |           |         |            |
| No Response    | 3         | 1.02    |            |

### Overall, this activity was effective in improving my knowledge in the content areas presented:

| Response       | Frequency | Percent | Mean: 1.15 |
|----------------|-----------|---------|------------|
| Strongly Agree | 251       | 85.37   |            |
| Agree          | 37        | 12.59   |            |
| Neutral        | 3         | 1.02    |            |
| Disagree       | 0         | 0.00    |            |
| Strongly       | 0         | 0.00    |            |
| Disagree       |           | r       |            |
| No Response    | 3         | 1.02    |            |

### As a result of this activity, I have learned new and useful strategies for patient care:

| Response       | Frequency | Percent | Mean: 1.25 |
|----------------|-----------|---------|------------|
| Strongly Agree | 223       | 75.85   |            |
| Agree          | 58        | 19.73   |            |
| Neutral        | 7         | 2.38    |            |
| Disagree       | 0         | 0.00    |            |
| Strongly       | 0         | 0.00    |            |
| Disagree       |           |         |            |
| No Response    | 6         | 2.04    |            |

### As a result of this activity, I have learned new strategies for patient care. List these strategies:

### Response

Use of proper diagnostic tools

Listen to patient, identify ADHD-diagnose, identify compliance in patients

Teamwork

Treatment in patients with intolerant statin therapy, diagnosing modalities in office for pulmonary HTN

Diagnosis of ADHD in adults, new drug for HF and guidelines, management of hyperlipidemia and OAB

Assess every case with anxiety or depression for ADHD

Monitor patient/send to Echo early with Dyspnea

Screening for ADD

Use more screening scales, incorporate new treatment guidelines and strategies learned today in patient care

New modalities for treating OAB. Treatments (new) for heart failure. Screen for ADHD

New strategies in ADHD treatment

Utilize the screening tools appropriately

Increase use of SGLT2 inhibitor in appropriate patients

Reinforce/continue

Evaluation; clinical criteria and management, implementing new treatment strategies

Management of DMII using SGLT2 inhibitor to facilitate not only gluco management but also weight loss

How to deal with adult ADHD in clinical setting

### Response

Assessment, screening, treatment, evaluation strategies

Integrating PCSK9 inhibitors, tibial nerve stimulation, Invokanna, assessing for Pulmonary hypertension, etc.

Management of hypercholesterolemia, Diabetes, and heart failure

Better understanding of evidence-based treatments, ability to provide improved, individualized care

Diagnosing and initiating treatment for ADHD. Treating OAB. Adjusting care in HF as needed

Use of different drugs

Better patient assessment skills/understanding of meds to treat common diagnoses

Better assessment through identified testing, effective use of medications, combination therapy

Screening tools, new treatments available that I can bring back to my practice

Use SGLT2 more frequently, ADHD RS

To practice what I have learned

Implement strategy to diagnose adults with ADHD. More aggressive in diagnosing PAH and referring to CTR S/aggressive to treat ASHD

Initiate SGLT2 inhibitor therapy, use ADHD RS questionnaire in practice, consider Echo more with Dyspnea evaluation, continuation therapy for OAB

Better diagnosis/treatment of DM, ADHD, PAH, Hyperlipidemia, OAB, HF

Current evidence based treatment regimen

Improve my diagnostic and therapeutic skills in the disease states we exposed here

**Evaluation of PAH** 

More comfortable in prescribing some medications, be more involved with ADHD

Speakers emphasized open communication with patients in order to engage with their treatment plan

Diagnosis of ADHD with ADHD-RS scale, treat OAB in office

Increase use of SGLT2

Education; follow up, correct drugs

If I still practiced

How to diagnose and treat OAB. How to evaluate heart failure

Implement cholesterol lowering drugs

Diagnose and treat patients with ADHD

PCSK9 consider research EMA study, ASKS screener use more, increase statin; ASK - if wear diapers, watch for Ivabradine study

ADHD screening tool

SGLT2 should not be used with patient with fracture. To implement new heart guidelines and drugs in my practice

Regarding pulmonary hypertension, will be more aggressive with initial workup before referral

Implementing the use of an ADHD screening tools

Use of SGLT2 inhibitors, prescribing drugs to treat ADHD, workup of diagnosis of PAH, injectable therapy for cholesterol

Use of screening tools, more confident in Rx

Screening and diagnostic tools

Use of questioning for ADHD and PAH. Lipid formulary. Decision on using SGLT2 inhibitors. Screening for ADHD. More detailed history in OAB

N/A

Up to date guidelines, easy ways to implement guidelines

ADHD - using self-report scale screening PAH or doing an echocardiogram

Management of heart failure patients who also have liver cirrhosis too

Using what's taught in conference, putting in my practice

### Response

Prescribe more SGLT2, when appropriate. Consider diagnosing ADHD according to guidelines. Preserve LDL-receptors is the clue to lowering LDL over 190

SGLT-2s can cause hypotension (orthostatic), spirometry reimburses better than EKG, statins can cause regression of atherosclerosis

Treatment options

Feel more comfortable with ADHD Dx2 treatment, PAH diagnosis and treatment, Heart failure management

Teamwork

SGLT-2 inhibitor for DMII management, proper screening for ADHD and depression

Drug therapy, more in depth assessment approach, more critical thinking, multifaceted approach to the problem

Knowing the extent to which primary care can identify and manage ADHD; appropriate, step-wise approach to managing patients with CHD and elevated LDL

Using the ASRS tool, Echo for PAH

Tibial nerve stimulation for OAB

Use of ASRS-V1.1 screener for ADHD

Identifying and approach to ADHD, PAH

Using a new class of DM medications; suspecting PAH in certain clinical settings

Using SGLT-2 safety/indications/side effects, screening ADHD tools and indications, PCSK9, indication, OAB management

Diabetes management

ADHD screen, Diabetes medication initial therapy, lipid management with statins, evaluation for OAB

Encourage patient to try new DM meds, assist in insurance coverage, identify ADHD, CHF plan

Provide written questionnaire for ADHD. Be more vigilant to the possibility of PAH

Proper assessment tools, treatment options

More in depth pre counseling/frequent follow up

Asking more questions, quality questions

Multiple

Screen ADHD; use OAB meds; increase use of SGLT2

Better evaluation of ADHD, diagnosis of pulmonary hypertension, diagnosis of OAB

Screening for ADHD

ASRS screening, use of PCSK9 when indicated

Recommend PCSK9 in high risk statin intolerant patients. Implement use of ADHD screening tools

Use of screening tools, monitoring, and confidence

SGLT-2 inhibitor for DMII management. Proper screening for ADHD and depression

Implementing screening tools

Due to the strict protocol where I work (correctional), I cannot use the new medications. Mental health treatment is separate from clinical treatment

Using evaluation tools for diagnosis and screening ADHD

Effective treatment per guidelines for HF, Dyslipidemia and new statin medications

Managing diabetes, keeping ADHD patient, introducing PSA9

Adjust basal insulins and employ SGLT-2 meds. Continue LDL treatment beyond targets, increase suspicion for adult ADHD

Diagnose PAH. Screen for ADHD

Screen adults for ADHD. Basic workup to identify PAH

Confidence in use and management of diabetic patient with meds. Diagnosis, identification of patient with ADHD, incorporate in my practice knowledge gained at this conference

Counsel patients with comorbidities about risks and benefits of using appropriate screening tools during assessments of patients and pharmaceutical therapy

### Response

Identifying how to implement new methods, also better way of explaining things to the patient

Utilizing SGLT-2 inhibitors more, screening for ADHD, use of PCSK-9 inhibitors, addressing OAB, use of newer drugs in heart failure

Using screening methods effectively for better treatment plan

Improve assessment, diagnosis, and apply or implement treatments accordingly

Screen patients better for diagnoses of certain conditions and better use of medications

Use of T2DM in management of DM, scales used in diagnosis of ADHD

ADHD usually has second mood disorder and be aware of those and should talk with family members as well

Start screening for ADHD more often, consider Invokana to be started earlier for treatment of DM. Increase diagnosis of PAH and treatment

Patient-family involvement

Better understanding of OAB management. Use of SGLT-2 in Diabetes care

Proper use of medications for HF and DM. Treatment for OAB

More diet, exercise, take the appropriate medication

Improve assessment and apply proper treatment

Use of SGLT-2, ADHD forms, right heart cath importance, PCSK-9 effect, B3 - treat OAB

Treating familial hypercholesterolemia

Management of T2DM with SGLT-2 inhibitors; use of ASRS screening tool; screening for OAB

Visuals, examples

LDL monitoring

Better client screening, more provider knowledge of treatment options, more scientific knowledge of disease processes

To screen depressed/anxious adult patients for ADHD

How to properly diagnose and pay close attention to symptoms

Use screening tools/many need more than one med therapy

Use and educate patients on the new guidelines for new used medications

Evaluation of ADHD and treatment

More accurate use of SGLT-2 drugs. ADHD management in adults. Better understanding of PAH and cholesterol management

Evaluating and treating patient with ADHD

Diabetes. ADHD. Hypercholemia

Use of Invokana. Tools to help diagnose ADHD. Evaluate PAH - echocardiogram. LDL goals under 70 - treatment options, new guidelines

Work up - diagnosis - treatment options

Better diagnosis and treatment

Implement ADHD screening tools; ASRS; ADHD Rx, order Echocardiogram. Consider acting non-statin medication

Use SGLT-2 early, screen for ADHD, consider PCSK9

Better implementation of diagnostic strategies and treatment according to guidelines discussed

Perform walk test, GBM, MD monitor PAH, dual PI in anxiety, depression in THC, A&B screening test

Treatment of OAB

New meds for LDL. Questions for ADHD is great, but no time for questioning

New drugs and treatment of LDL and resistance to statins. Use of adult self report scale and ADHD

New screener for ADHD. More aggressive checks for PAH. PCSK-9!

ADHD new guidelines in treating newly diagnosed adolescents and adults - nonamphetamine drug use (subsets do better with this)

More awareness of ADHD and screening

Assessing for ADHD, OAB were very useful

### Response

**FACE - Diabetes:** 

ADHD screen tests, different intensity of statins, diagnostic tests for PAH, drug treatment in OAB like Beta 3 Agonists My ability to screen with appropriate tests and more properly treat

### How likely are you to implement these new strategies in your practice?

| Response        | Frequency | Percent | Mean: 1.37 |
|-----------------|-----------|---------|------------|
| Very likely     | 208       | 70.75   |            |
| Somewhat likely | 69        | 23.47   |            |
| Unlikely        | 2         | 0.68    |            |
| Not applicable  | 12        | 4.08    |            |
| No Response     | 3         | 1.02    |            |

## No Response 3 1.02 In terms of delivery of the presentation, please rate the

effectiveness of the speaker: Jeff Unger, MD, ABFM,

| Response       | Frequency | Percent | Mean: 4.89 |
|----------------|-----------|---------|------------|
| Excellent      | 252       | 85.71   |            |
| Very Good      | 26        | 8.84    |            |
| Good           | 3         | 1.02    |            |
| Fair           | 0         | 0.00    |            |
| Unsatisfactory | 0         | 0.00    |            |
| No Response    | 13        | 4.42    |            |

## In terms of delivery of the presentation, please rate the effectiveness of the speaker: Franck Rahaghi, MD, MHS, FCCP - PAH:

| Response       | Frequency | Percent | Mean: 4.82 |
|----------------|-----------|---------|------------|
| Excellent      | 237       | 80.61   |            |
| Very Good      | 42        | 14.29   |            |
| Good           | 5         | 1.70    |            |
| Fair           | 0         | 0.00    |            |
| Unsatisfactory | 0         | 0.00    |            |
| No Response    | 10        | 3.40    |            |

## In terms of delivery of the presentation, please rate the effectiveness of the speaker: Matt T. Rosenberg, MD - OAB:

| Response       | Frequency | Percent | Mean: 4.94 |
|----------------|-----------|---------|------------|
| Excellent      | 246       | 83.67   |            |
| Very Good      | 15        | 5.10    |            |
| Good           | 0         | 0.00    |            |
| Fair           | 0         | 0.00    |            |
| Unsatisfactory | 0         | 0.00    |            |
| No Response    | 33        | 11.22   |            |

### When do you intend to implement these new strategies into your practice?

| Response       | Frequency | Percent | Mean: 1.49 |
|----------------|-----------|---------|------------|
| Within 1 month | 205       | 69.73   |            |
| 1-3 months     | 48        | 16.33   |            |
| 4-6 months     | 10        | 3.40    |            |
| Not applicable | 24        | 8.16    |            |
| No Response    | 7         | 2.38    |            |

## In terms of delivery of the presentation, please rate the effectiveness of the speaker: C. Brendan Montano, MD - ADHD:

| Response       | Frequency | Percent | Mean: 4.83 |
|----------------|-----------|---------|------------|
| Excellent      | 245       | 83.33   |            |
| Very Good      | 33        | 11.22   |            |
| Good           | 5         | 1.70    |            |
| Fair           | 0         | 0.00    |            |
| Unsatisfactory | 1         | 0.34    |            |
| No Response    | 10        | 3.40    |            |

## In terms of delivery of the presentation, please rate the effectiveness of the speaker: Laurence O. Watkins, MD, MPH, FACC - Hypercholesterolemia:

| Response       | Frequency | Percent | Mean: 4.85 |
|----------------|-----------|---------|------------|
| Excellent      | 233       | 79.25   |            |
| Very Good      | 31        | 10.54   |            |
| Good           | 5         | 1.70    |            |
| Fair           | 0         | 0.00    |            |
| Unsatisfactory | 0         | 0.00    |            |
| No Response    | 25        | 8.50    |            |

## In terms of delivery of the presentation, please rate the effectiveness of the speaker: Icilma V. Fergus, MD, FACC - Heart Failure Part I:

| Response       | Frequency | Percent | Mean: 4.82 |
|----------------|-----------|---------|------------|
| Excellent      | 197       | 67.01   |            |
| Very Good      | 34        | 11.56   |            |
| Good           | 3         | 1.02    |            |
| Fair           | 1         | 0.34    |            |
| Unsatisfactory | 0         | 0.00    |            |
| No Response    | 59        | 20.07   |            |

In terms of delivery of the presentation, please rate the effectiveness of the speaker: Icilma V. Fergus, MD, FACC - Heart Failure Part II:

| Response       | Frequency | Percent | Mean: 4.83 |
|----------------|-----------|---------|------------|
| Excellent      | 184       | 62.59   |            |
| Very Good      | 32        | 10.88   |            |
| Good           | 3         | 1.02    |            |
| Fair           | 0         | 0.00    |            |
| Unsatisfactory | 0         | 0.00    |            |
| No Response    | 75        | 25.51   |            |

To what degree do you believe that the subject matter was presented fair, balanced, and free of commercial bias? Jeff Unger, MD, ABFM, FACE - Diabetes:

| Response       | Frequency | Percent | Mean: 4.84 |
|----------------|-----------|---------|------------|
| Excellent      | 241       | 81.97   |            |
| Very Good      | 32        | 10.88   |            |
| Good           | 6         | 2.04    |            |
| Fair           | 0         | 0.00    |            |
| Unsatisfactory | 0         | 0.00    |            |
| No Response    | 15        | 5.10    |            |

To what degree do you believe that the subject matter was presented fair, balanced, and free of commercial bias? Franck Rahaghi, MD, MHS, FCCP - PAH:

| Response       | Frequency | Percent | Mean: 4.91 |
|----------------|-----------|---------|------------|
| Excellent      | 262       | 89.12   |            |
| Very Good      | 19        | 6.46    |            |
| Good           | 4         | 1.36    |            |
| Fair           | 0         | 0.00    |            |
| Unsatisfactory | 0         | 0.00    |            |
| No Response    | 9         | 3.06    |            |

To what degree do you believe that the subject matter was presented fair, balanced, and free of commercial bias? Matt T. Rosenberg, MD - OAB:

| Response       | Frequency | Percent | Mean: 4.89 |
|----------------|-----------|---------|------------|
| Excellent      | 233       | 79.25   |            |
| Very Good      | 22        | 7.48    |            |
| Good           | 1         | 0.34    |            |
| Fair           | 0         | 0.00    |            |
| Unsatisfactory | 1         | 0.34    |            |
| No Response    | 37        | 12.59   |            |

In terms of delivery of the presentation, please rate the effectiveness of the speaker: Laurence O. Watkins, MD, MPH, FACC - Heart Failure Part II:

| Response       | Frequency | Percent | Mean: 4.85 |
|----------------|-----------|---------|------------|
| Excellent      | 185       | 62.93   |            |
| Very Good      | 26        | 8.84    |            |
| Good           | 2         | 0.68    |            |
| Fair           | 1         | 0.34    |            |
| Unsatisfactory | 0         | 0.00    |            |
| No Response    | 80        | 27.21   |            |

To what degree do you believe that the subject matter was presented fair, balanced, and free of commercial bias? C. Brendan Montano, MD - ADHD:

| Response       | Frequency | Percent | Mean: 4.88 |
|----------------|-----------|---------|------------|
| Excellent      | 256       | 87.07   |            |
| Very Good      | 25        | 8.50    |            |
| Good           | 3         | 1.02    |            |
| Fair           | 0         | 0.00    |            |
| Unsatisfactory | 1         | 0.34    |            |
| No Response    | 9         | 3.06    |            |

To what degree do you believe that the subject matter was presented fair, balanced, and free of commercial bias? Laurence O. Watkins, MD, MPH, FACC - Hypercholesterolemia:

| Response       | Frequency | Percent | Mean: 4.86 |
|----------------|-----------|---------|------------|
| Excellent      | 247       | 84.01   |            |
| Very Good      | 30        | 10.20   |            |
| Good           | 2         | 0.68    |            |
| Fair           | 0         | 0.00    |            |
| Unsatisfactory | 1         | 0.34    |            |
| No Response    | 14        | 4.76    |            |

To what degree do you believe that the subject matter was presented fair, balanced, and free of commercial bias? Icilma V. Fergus, MD, FACC - Heart Failure Part I:

| Response       | Frequency | Percent | Mean: 4.85 |
|----------------|-----------|---------|------------|
| Excellent      | 210       | 71.43   |            |
| Very Good      | 23        | 7.82    |            |
| Good           | 5         | 1.70    |            |
| Fair           | 0         | 0.00    |            |
| Unsatisfactory | 1         | 0.34    |            |
| No Response    | 55        | 18.71   |            |

To what degree do you believe that the subject matter was presented fair, balanced, and free of commercial bias? Icilma V. Fergus, MD, FACC - Heart Failure Part II:

| Response       | Frequency | Percent | Mean: 4.84 |
|----------------|-----------|---------|------------|
| Excellent      | 200       | 68.03   |            |
| Very Good      | 26        | 8.84    |            |
| Good           | 3         | 1.02    |            |
| Fair           | 0         | 0.00    |            |
| Unsatisfactory | 1         | 0.34    |            |
| No Response    | 64        | 21.77   |            |

To what degree do you believe that the subject matter was presented fair, balanced, and free of commercial bias? Laurence O. Watkins, MD, MPH, FACC - Heart Failure Part II:

| Response       | Frequency | Percent | Mean: 4.84 |
|----------------|-----------|---------|------------|
| Excellent      | 195       | 66.33   |            |
| Very Good      | 26        | 8.84    |            |
| Good           | 1         | 0.34    |            |
| Fair           | 0         | 0.00    |            |
| Unsatisfactory | 2         | 0.68    |            |
| No Response    | 70        | 23.81   |            |

Which statement(s) best reflects your reasons for participating in this activity:

| participating in this activity. |           |         |         |  |
|---------------------------------|-----------|---------|---------|--|
| Response                        | Frequency | Percent | Mean: - |  |
| Topics covered                  | 236       | 80.27   |         |  |
| Location/ease of access         | 193       | 65.65   |         |  |
| Faculty                         | 71        | 24.15   |         |  |
| Earn CME credits                | 218       | 74.15   |         |  |
| No Response                     | 12        | 4.08    |         |  |

Future CME activities concerning this subject matter are necessary:

| Response             | Frequency | Percent      | Mean: 1.41 |
|----------------------|-----------|--------------|------------|
| Strongly agree       | 185       | 62.93        |            |
| Agree                | 84        | 28.57        |            |
| Neutral<br>Disagree  | 17<br>0   | 5.78<br>0.00 |            |
| Strongly<br>Disagree | 0         | 0.00         |            |
| No Response          | 8         | 2.72         |            |

What topics would you like to see offered as CME activities in the future?

### Response

Scale-coronary syndrome

Pharmacology, Dermatology, chronic pain management

Wound care, up to date insurance coverage plan

PVD

Hepatic stenosis, COPD, Rheumatoid Arthritis, managing heart failure in Primary Care, treating dyslipidemia in high LFT's

Effective HTN management in patient with refractory treatment

Allergy, asthma, Immunology, Dermatology

Any on latest strategies

**Neurological Disorders** 

Hypertension uncontrolled

Dementia

Thyroid disease, PAD, ED, Venous Disease

PCOS, DM-2, CHF, Infectious Disease, Kidney Failure, Sleep Apnea

Depression, COPD, STDs

Anemia, COPD

Women's Health

AFib

Telephone medicine

**EKG** interpretation

COPD, Asthma

Renal pathology, DM, Pharmacotherapy, end stage renal diseases - maintenance

### Response

Way for older adults to lose weight and easy exercises to teach patients controlling blood pressure without multiple medications

The state of healthcare today

Hypo/hyperthyroid. CAD. COPD

More diabetes, hypertension

High risk pregnancy

**Urgent Care** 

Thyroid nodules and cancer. Renal failure

Neurological evaluation by Primary Care

Wound care, telemedicine (pressure ulcer, vascular ulcer, arterial ulcer)

Immunology, allergies, weight loss, Dermatology

HIV

Autoimmune diseases

Breast, prostate and colon cancer - chronic kidney disease

Atrial Fibrillation

Hormonal replacement, weight loss, Vitamin therapy, Botox, off-label treatments

Anticoagulants

HTN and any Primary/DDM care topic

IBS, Crohn's Disease and management

Basic CV discussion

Diagnosing psychiatric disorder

COPD, Asthma, blood disorders

MI, EKG, CXR, lab values

Rheumatology

Genetics - genetic testing of various diseases and treatment/prevention

Further Diabetes topics including insulin therapy

Hypogonadism, interpretation of lab values, prostate evaluation

Endo, musculoskeletal, Women's Health, Psychology, Bioterrorism

Depression/anxiety in the elderly, treatment update

Open

Diseases specific to the pediatric population

Weight loss meds, more DM, HTN, more psychological disorders

HTN, DM, Parkinson's, pain, etc.

HIV, domestic violence, risk management

Psychiatric disorders in Primary Care, musculoskeletal management/assessment

Seizures and hypo-hyperthyroidism

Treatment of HIV disease, autoimmune disease, SLE, RA, etc.

How to approach addiction

Pulmonary Disease, vascular disease

Any Internal Medicine topics

Endocrine, ENT

COPD, PVD, essential, essential. Hypertension, coronary artery disease

Oncology

Immunizations, skin disease, stroke

Thyroid disease

Response

Diabetes, Prostatitis, Scrotal pain, asthma, COPD, medically-managed weight loss

Thyroid conditions, Alzheimer's, anticoagulation with newer drugs

Medical tests, updates

Pain management

Dermatology updates

More in Diabetes treatment besides SGLT

Dermatology; Lymphedema

Resistant hypertension

Stroke

Bioidentical hormones, hypothyroid treatment

Update hypertension evaluation and treatment

Women's Health, prostate screening/cancer

Lupus. Multiple Sclerosis. Breast Cancer

Hypertension treatment, management. Back pain management

Breast cancer/prostate cancer screening. Asthma/COPD management

Pediatrics, Orthopedic

STDs, ORI throat infections. Allergic rhinitis/sinusitis

Dermatology. Orthopedic evaluation

Management of hypertension, CKD, CVA

GI related, Infectious

Peripheral Artery Disease, Endocrine Disorders

Respiratory - Immunology infections

Patients becoming resistant to antibiotics, how to solve, prevent it, when it occurs what do we do?

Musculoskeletal/pain management

Screening and management of depression and anxiety in Primary Care. Antibiotic stewardship in Primary Care (from an Infectious Disease specialist's perspective)

Alternative medicine

Tumors that don't present on imaging. Treatment and outcomes on rare cancers, Neurovastomas

Psychiatric conditions

Thyroid disease. Sleep apnea

Management of CHF and cardiac arrhythmias

Vaccines - past and present trends, concepts, expectations

End of life care and new directive

Pictures in Dermatology

**HBO** therapy

Dementia screening. CAD treatment guidelines. Pressure treatment in elderly guidelines

Endocrinology; Neurological conditions in Primary Care

Obstetric care

Vascular surgery. Endovascular surgery

Gastroenterology/ID

I recommend insurance/CPI/ICD10; tele-medicine in Primary Care which is important to explore - TQ

Zika!

Women's Health. Related topics. STDs. Osteoporosis. Pelvic pain

Rheumatologic diseases

CVA, Hepatic Stenosis

Response

DM prevention

Common dermatology in Primary Care

Basic psych (depression, anxiety), thyroid

Thyroid dysfunction, infectious diseases

Infectious disease, myeloproliferative disease

Update on genomic analysis and correlation with common disease

Infectious Disease

PCOS. Menopause. More cardiac (always). Neurological - headache

**Immunizations** 

Related to Primary Care practice/GI/Hepatology

Cancer screening in Primary Care, smoking cessation

GI management

Obstructive sleep apnea, autoimmune Encephalopathy

Hypertension, heart failure, kidney disease

Obesity, Dermatology, vaccine update for adults

Cancer treatment, PCOS treatment

Severe hypothyroidism

Bipolar disorder. Insomnia

Stroke and ischemic and hemorrhagic seizures, SAH, stroke, TPA

Stroke/SAH/Infectious Disease

Depression, G.I.

Dermatology, Ophthalmology, Diabetes

Information on HIV, Psoriasis, cancer in Primary Care, psychology in Primary Care, COPD, PCOS, RA, Hepatitis, acne, mental health

Insect borne infection/parasitic infection and MRSA

HIV. HCV

MI, Alzheimer's, CKD

Score cards, pain management

Treating behaviors of Dementia; managing treatment-resistant Depression

Geriatric care, HTN

Connective tissue diseases, Hypertension, topic of endocrinology

Arrhythmia symposium. HIV update. Multiple Sclerosis update. Pharmacotherapy - opioid safety

More diabetes

ESRD, thyroid disorder, adrenal insufficiency, Pheochromocytoma

Use of CGM in Diabetes (eg Dexom). Back pain management in Primary Care settings, lung nodules, when to be more concerned, ILD

Arrhythmias, autoimmune disorders

Non-Diabetic vascular disease

Hypertension, CAD, COPD, Asthma

Open

Nephrology, Respiratory, Psychiatry, Dermatology, Rheumatology

Diabetes, Neurology

HTN (new meds). Screening test required per Medicare

Hypertension, cancer screening, obesity

Women's Health issues, mental health (Bipolar/Depression)

Menopause, hormonal/nonhormonal, diagnosis and risks, HTN, asthma. More Women's Health

Response

Colon cancer/colorectal surgery; Neurology - migraine/Alzheimer's Disease

Asthma/COPD

Obesity, Erectile Dysfunction, Chronic Pain

Rehab medicine - SCI, CVA

Any in medicine

DM Type 2, HTN, CAD, COPD

Psych-Depression, Schizoaffective disorder, anxiety, eating disorder

Dermatology, Osteopenia/Osteoporosis

Brain tumors and treatment strategies; inflammatory skin diseases, back pain, BPH, prostate cancer, seizure disorders, PCOS, headaches

HTN, sports medicine, LBP

Psych, more ADHD, sleep apnea, insomnia, substance abuse, testosterone replacement

Mx of hypertension, mx of Osteoporosis

Arrhythmias, ACS, CHF, Congenital Heart Disease, CAD

Legal issues in clinical practice

Dermatology - diagnosis - visual (slides)

Bipolar Disorder in adults

COPD/CKD/Dermatology

Endocrinology, Rheumatology, Neurology

Treatment of hypertension; Asthma, COPD, Pneumonia, TB

Schizophrenia, mood disorders

Geriatric disorders, obesity management

Narcotic prescriptive authority, recognizing impairment in the workplace

Renal

HIV/AIDS

Obesity

COPD/HTN/Kidney Disease/Dermatology - wound care/Arthritis RA

Drug to drug interaction and major side effects and contraindications

HIV, Prep, PeP

Heart Failure, chronic pain, Alzheimer's, sickle cells

Hematological disorders

Infectious Disease. Renal disease

Anxiety disorder. Renal disease

Heart Failure, medical marijuana, mood disorders, headaches, Women's Health, Men's Health, controlled substance prescription and addiction

Anticoagulant study, Coumadin therapy, the difference between different types

**Primary Care topics** 

Dermatology, obesity

Depression, COPD, hypothyroidism, HTH treatment for the office, urgency

ICD impact in real medicine and patient care. HEIDIS and daily medicine. Lack of time to do good medicine, poor reimbursement and government ownership

Antibiotic treatment. CVA. Osteoporosis

GI/Pediatrics

Hormone replacement

Business in medicine

Liver failure, M. Gravis, ALS, Orthopedics, ulcers - GI, renal failure

### Response

HF, Diabetes, Neurological Disorders

Psych. Substance abuse. Pulmonary. Hormones

Bipolar, CPT code, RA, CKD, Obesity, HRT, NASH, PAH again, lecture for medication combination strategies

Musculoskeletal/ortho

Addiction medicine (heroine, THC, cocaine)

#### Additional comments:

### Response

Wonderful CME

Very informative conference

Good program

Great presenters

Great review and introduction of information

Very informative lectures, great faculties

I don't think pulmonary hypertension would help me in my practice

Thank you very much for providing a great learning environment

Excellent - excellent sessions

Consider hot lunches

This conference is very educational. I will invite my friends to participate in future ones

Excellent

The length of the program was adequate, the breaks were timely, the food provided was variously good, the room was comfortable, the speakers were able to provide education professionally and effectively

Great presentations

Wonderful presentation

The CV discussions were interesting, but over my head. I am a new graduate FNP. There were too many abbreviations and new meds. Also, this is a lecture that should take place near the beginning of the CMEs - not the end. That is my perspective

Really enjoyed the interactive component of the presentations

Comfortable venue. Excellent, knowledgeable speakers

I loved the speakers Drs. Watkin, Rosenberg, Rahaghi

Great CME activity

Enjoyed OAB speaker Dr. Rosenberg after lunch! All speakers were excellent. Pre and post test very helpful

Excellent course. I will attend again next year

Thank you! Very well organized

Great conference

Excellent symposium

Good review and updates

Excellent presentation, informative, improved my clinical skills

Thank you

Very good! Many strategies to review and begin using. Thank you

Great speakers and excellent, informative, which is applicable to clinical practice

Well done conference - thank you!

Great conference! Every single presentation was wonderful, very engaging and informative

This is my frist time attending your conference and it's wonderful!

Excellent conference

#### Additional comments:

### Response

Very good

Thank you for a day full of knowledge and good company

It was hard to see the video screen from mi-auditorium

Excellent course, thank you

Excellent

Could we get handouts containing the slides shown by the speakers?

It seems this CME course is almost the same as the last one, could it be different contents in the future?

This was a great, educational conference. Great presentations! Thank you

Thank you

Great conference. Thank you for the opportunity

Excellent topics reviewed

Dr. Unger lecture was very beneficial. Please bring him back. Made it simple with his research. Great conference. Enjoyed the lecture. Learned a lot. Since there were a lot of NPs in the group, consider having at least 1 Nurse Practitioner to lecture. Location is too west. Can you consider moving this conference somewhere in the middle, like Plantation?

**Excellent conference** 

Vascular heart disease

I wish all the speakers spoke the way Dr. Watkins does! I am white, by the way

Thank you for a wonderful conference!

Very nice organized and conducted conference as always. TQ for all staff of NACE. Would be nice if the downloaded slide could stream/display the topic of conference on that day only; there are too many slides to download online and it is not aligned to the sequence of the conference presentation. Could improve better - TQ

**Excellent presentations** 

Dr. Rosenberg was excellent. Simplified approach

Cardiologist Dr. Ferens could do well lecturing other cardiologists. As a PCP I found her lecture not applicable to my practice (Internal Medicine)

Very good information

Great sessions

Excellent location

Great conference! Very helpful topics

Very good service for PAS, NPS

Thank you!

Great conference

I always enjoy these conferences

This is an excellent program

Great conference, very informative and interesting

Overall impressive conference

Great with location, organization, faculty, and audio

Very good presentations

Continued conferences on the current topics in evolution: new strategies in common diseases: Diabetes, CHF, Hypertension, COPD, more conference on geriatric treatment

Providing electrical strip to each table to connect iPad or laptop would be helpful

Excellent program

Excellent CME program. Thank you NACE and Dr. Sherman

Excellent

Well spent day

Amazing conference, please keep me informed of future events

#### Additional comments:

### Response

Very knowledgeable discussion, Thanks!

**Excellent program** 

Excellent educational program

Excellent conference. Dr. Rosenberg is an awesome speaker

Very good

**Excellent conference** 

**Excellent presentations** 

Great presenters! Thank you!

Thank you

Less starch options, more protein, fresh produce

Did not appreciate hotel staffing locking people out of conference room at lunch. NACE staff rude in afternoon - making noise in hall and when asked to tone down they didn't care

Excellent speakers!

HF was a heavy topic. I think I would have paid better attention if it was presented earlier in the day

Great planning and thank you for no cost program. Great topics and faculty. We need slides available to us to look over talks

Very informative and organized

Please, please, please add a protein source to breakfast and snacks! Especially at a Diabetes discussion! One suggestion is boiled eggs!

Excellent conference, great location

Dr. Fergus needs to simplify - very confusing - esoteric information. Very well organized, great speakers - thank you!

Great speakers, great topics. I enjoy interactive questions

Very informative lectures

Thank you for the invitation

Great CME conference

Good location, good speakers, good topics, thanks

The presenters were engaging and funny and to the point! Dr. Rosenberg is amazing! So funny!

More interactive activities. The pre and post tests are good. Excellent conference! Last presentation very profitable!

Very appreciative that these CME are offered 'free' and in 'class' locations! Lunch provided and quality educational content! Thanks!

Thank you. Staff at Marriott was attentive

Get female speakers!